Skip to main content
. 2016 Mar 30;36(13):3777–3788. doi: 10.1523/JNEUROSCI.0451-15.2016

Figure 8.

Figure 8.

Effect of bindarit on CCL2, CCL5, CCR2, IL-1β, and TLR2 expression. A, CCL2 protein levels were reduced by −77.4% in serum of bindarit-treated animals compared with control mice (t test, p = 0.01), 4 h after LPS challenge. B, C, CCL2, CCL5, CCR2, IL-1β, and TLR2 mRNA levels measured by qRT-PCR in blood (B) and in the hippocampus (C) of control (MC) or bindarit (Bin) treated epileptic mice, 4 h after LPS injection. In the blood, bindarit dampened CCL2 and CCL5 mRNA levels (t test, p < 0.01) and increased CCR2 expression (t test, p < 0.01; B). In the hippocampus, bindarit downregulated CCL2, CCL5, IL- 1β, and TLR2 mRNAs while increasing CCR2 mRNA (t test, p < 0.0001 for CCL2, p < 0.02 for CCL5, p < 0.0001 for IL-1β, p < 0.0005 for TLR2, and p < 0.0001 for CCR2; C). *p < 0.05; **p < 0.01; ***p < 0.001.